Deerfield Management Company, L.P. (Series C) Revolution Medicines, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.35 Billion
- Q2 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Revolution Medicines, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 3,384,072 shares of RVMD stock, worth $168 Million. This represents 2.86% of its overall portfolio holdings.
Number of Shares
3,384,072
Previous 3,317,332
2.01%
Holding current value
$168 Million
Previous $117 Million
6.14%
% of portfolio
2.86%
Previous 2.97%
Shares
14 transactions
Others Institutions Holding RVMD
# of Institutions
334Shares Held
195MCall Options Held
908KPut Options Held
723K-
Vanguard Group Inc Valley Forge, PA15.8MShares$783 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA14.3MShares$712 Million2.37% of portfolio
-
Black Rock Inc. New York, NY13.4MShares$666 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X010.6MShares$526 Million0.2% of portfolio
-
Wellington Management Group LLP Boston, MA10.3MShares$510 Million0.07% of portfolio
About Revolution Medicines, Inc.
- Ticker RVMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,697,600
- Market Cap $4.36B
- Description
- Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...